High Quality Finasteride Powder for Hair Loss 99% CAS 98319-26-7
TDS 24 Inquiries
98319-26-7
Pharmaceutical Grade
98%
china any port
TNJONE
1kg ,25kg or according to customer's detail requirement.
2025-12-30
Semaglutide,Tirzepatide,API,Vitamins,Food Additive
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOff-White Crystalline Powder
Solid
Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane.|Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures. In 1998, it was approved by the FDA to treat male pattern hair loss. Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by in situ high levels of DHT. In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.|Finasteride is a 5-alpha Reductase Inhibitor. The mechanism of action of finasteride is as a 5-alpha Reductase Inhibitor.|Finasteride is a 5-alpha reductase inhibitor used to treat symptoms of benign prostatic hypertrophy and male pattern baldness. Finasteride is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of clinically apparent, acute liver injury.|Finasteride is a synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.|An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.CertificatesBasic Info-
Product Name:
Finasteride
Other Name:1H-Indeno[5,4-f]quinoline-7-carboxamide,N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-,(4aR,4bS,6aS,7S,9aS,9bS,11aR)-;4-Azaandrost-1-ene-17-carboxamide,N-(1,1-dimethylethyl)-3-oxo-,(5α,17β)-;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-Dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno[5,4-f]quinoline-7-carboxamide;MK 906;Finasteride;Proscar;Prostide;Propecia;Finpecia;Finastid;Chibro-Proscar;Fincar;Fistide;Finax;Finast;Finara;Prosteride;N-(tert-Butyl)-3-oxo-4-aza-5α-androst-1-ene-17-carboxamide;Finalo;Geffina;Appecia;Finasterid Alternova
CAS No.:98319-26-7
Molecular Formula:C23H36N2O2
InChIKeys:InChIKey=DBEPLOCGEIEOCV-WSBQPABSSA-N
Molecular Weight:372.54
Exact Mass:372.54
EC Number:1308068-626-2
UNII:57GNO57U7G
NSC Number:741485
DSSTox ID:DTXSID3020625
NCI Thesaurus Code:C1099
Color/Form:White to off-white crystalline solid
ATC Code:G04CB01|D - Dermatologicals|G - Genito urinary system and sex hormones
HScode:29379000
Categories:
Characteristics-
PSA:
58.2
XLogP3:3
Appearance:white to beige solid
Density:1.065±0.06 g/cm3(Predicted)
Melting Point:252-254 °C
Boiling Point:576.6°C at 760 mmHg
Flash Point:177.4ºC
Refractive Index:1.524
Water Solubility:H2O: insoluble ;DMSO: 32 mg/mL, soluble
Storage Conditions:Store at RT
Specific rotation:405 -59° (c = 1 in methanol)
Collision Cross Section:200 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Experimental Properties:MP approx 257 °C (dried to anhydrous under nitrogen)
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Tirzepatide,API,Vitamins,Food Additive
-
Location:
No. 4C-11-A392, Financial Port, Northwest corner of Fengjing Avenue and Fengxin Road, Fengdong New City, Xi 'an, Shaanxi Province
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
5
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2019
-
-
Inquiry History24 Inquiries
Country Product Purchase Quantity Date Posted 
Canada
High quality Pure 99% Finasteride powder CAS 98319-26-7
100 G Nov 16, 2023 
Pakistan
Finasteride
1 KG Aug 20, 2026 
Lebanon
Finasteride
50 G Dec 5, 2025 
Italy
Finasteride
1000 MG Apr 18, 2025
Pakistan
Finasteride
1 KG Nov 19, 2024 
Thailand
Finasteride
10 G Jul 8, 2024 
United States
Finasteride
10 G Mar 30, 2024 
Croatia
Finasteride
1 KG Sep 5, 2025
Croatia
Finasteride
20 G Sep 3, 2025
Italy
Finasteride
500 MG Apr 18, 2025 
New Zealand
Finasteride powder
10 G Sep 26, 2024 
Malaysia
Finasteride
100 G Aug 21, 2024
United States
Nitracaine (Crystal 99.9% min)
2 G Jun 11, 2024
Thailand
High purity Finasteride
100 G May 4, 2024 
United Kingdom
Finasteride
10 G Jan 10, 2024 
Germany
Finasteride
50 G Oct 23, 2024 
Spain
finasteride
20 MG Jun 29, 2026
Spain
Finasteride
1 KG Jun 28, 2026
United States
High purity Finasteride
20 G Feb 27, 2026 
South Africa
Finasteride
100 G Feb 20, 2026 Post an enquiry for this product
